(RETRANS) ChemoTech’s Animal Care Celebrates Record-Breaking Month with Order Intake of 200,000 USD

Retransmission of the press release that was published, with the associated MAR label, on May 1st, 2025, at 06:15 CET.

Scandinavian ChemoTech is proud to announce a record-breaking performance in April, with order intake near the total for the entire first quarter of the year. This achievement marks a significant milestone and sets a strong tone for the beginning of Q2.

“We are thrilled with the momentum we have seen as we move into the second quarter," said Mohan Frick, CEO. "Nearing our Q1 order volume in just one month is a testament to the hard work of our team and the trust our customers place in Tumor-Specific Electroporation (TSE)."

While the company is optimistic about the trajectory for Q2, the sales forecast for the remainder of the quarter is still uncertain. “While we are encouraged by this strong start, it’s too early to project how the rest of the quarter will unfold,” said Ann Ohlsson, Head of finance.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.